Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 167 across all filing types
Latest filing 2026-02-03 Share Issue/Capital Cha…
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo Pharmaceuticals gibt Privatplatzierung eigener Aktien bekannt
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the successful completion of a private placement of treasury shares by Cosmo Pharmaceuticals. It details the transaction, the investor involved, the strategic rationale, and the impact on the company's capital structure. While it mentions the sale of shares, it is specifically a corporate announcement regarding a capital-raising activity (private placement), which falls under the 'Capital/Financing Update' category. It is not a report publication announcement (RPA) because it provides the substantive details of the transaction rather than just announcing the availability of a report.
2026-02-03 German
Invitation to Cosmo’s Full Year 2025 Financial Results Webcast on 9 March 2026
Report Publication Announcement Classification · 1% confidence The document is an announcement regarding the upcoming publication of the 2025 Full-Year financial results and an invitation to a webcast presentation. It explicitly states that the actual Annual Report and ESG Report will be available for download on a future date (9 March 2026). Following the 'Menu vs Meal' rule, this document is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2026-01-28 English
Einladung zum Webcast von Cosmo zur Präsentation der Finanzergebnisse für das Geschäftsjahr 2025 am 9. März 2026
Report Publication Announcement Classification · 1% confidence The document is an announcement regarding the upcoming release of financial results and an invitation to a webcast presentation. It explicitly states that the actual reports (Annual Report 2025 and ESG Report) will be available for download on a future date (March 9, 2026). Following the 'Menu vs Meal' rule, this document is an announcement of a report publication, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2026-01-28 German
Cosmo Enters Scale Up Phase with €104M Revenue, €128M Cash, and Breakout AI and Dermatology Platforms
Earnings Release Classification · 1% confidence The document is a press release titled 'Cosmo Enters Scale Up Phase' that provides preliminary, unaudited financial results (revenue and cash position) for the fiscal year 2025. It explicitly states that the audited consolidated financial statements and annual reports will be published at a later date (March 9, 2026). Because this is an initial announcement of financial highlights rather than the full audited report, and it serves to inform the market of performance metrics, it is classified as an Earnings Release (ER). FY 2025
2026-01-12 English
Mit einem Umsatz von EUR 104 Mio., EUR 128 Mio. an Cash sowie bahnbrechenden KI- und Dermatologie-Plattformen tritt Cosmo in die Scale-up-Phase ein
Earnings Release Classification · 1% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) from Cosmo Pharmaceuticals providing preliminary, unaudited financial results for the fiscal year 2025. It highlights key financial metrics like revenue and cash position, discusses business updates, and explicitly states that the audited annual report will be published at a later date (March 9, 2026). Since this is the initial announcement of financial results rather than the full annual report itself, it is classified as an Earnings Release. FY 2025
2026-01-12 German
Cosmo announces breakthrough Phase III Topline results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in male hair loss, showing up to 539% relative improvement in Target-Area Hair Count vs ...
Regulatory Filings Classification · 1% confidence The document is a press release announcing clinical trial results (Phase III Topline results for Clascoterone). It is not a formal financial report, audit, or proxy statement. It functions as a general regulatory announcement regarding company operations and clinical progress, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into more specific categories like Earnings Release (which would focus on quarterly financial results) or Investor Presentation (which would be a slide deck).
2025-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.